What is Achiko?
Achiko is dedicated to pioneering innovations within healthcare technology, operating through its biotechnology division, AptameX, and its digital mobile health technology division, Teman Sehat. The company has established a distinctive healthtech capability that integrates user-friendly diagnostic testing with a digital passport solution, primarily for the management of Covid-19. AptameX leverages cost-effective, chemically synthesized DNA aptamer-based technology, positioning it for broad application in the evolving diagnostic field. In conjunction with the Teman Sehat mobile health app, Achiko is developing technologies aimed at delivering rapid and affordable diagnostic testing for various pathogenic diseases and therapeutic indications. The AptameX technology, licensed from Regenacellx.sl, grants Achiko exclusive commercialization rights. Headquartered in Zurich, the company maintains offices in Hong Kong, Jakarta, Seoul, and Singapore.
How much funding has Achiko raised?
Achiko has raised a total of $19.3M across 3 funding rounds:
Share Placement
$5.3M
Debt
$12.7M
Debt
$1.3M
Share Placement (2021): $5.3M, investors not publicly disclosed
Debt (2022): $12.7M led by Riverfort Global Opportunities PCC
Debt (2022): $1.3M supported by Negma Group and Buranto
Key Investors in Achiko
Negma Group
Negma Group is a diversified investment fund specializing in debt and equity financing, venture capital, and quantitative trading. With a focus on innovative growth strategies, they aim to transform uncertainty into opportunity for entrepreneurs and investors globally.
Buranto
Buranto is an investment firm run by Annette and Derek Brandt, focused on helping individuals and small businesses grow their money by identifying good investment opportunities and providing clear financial advice tailored to client goals.
What's next for Achiko?
The recent major strategic investment positions Achiko for accelerated growth and further development of its integrated healthtech solutions. With a focus on expanding its diagnostic capabilities and digital health platform, the company is poised to capitalize on the increasing demand for rapid, accessible, and reliable health monitoring and management tools. This strategic financing is expected to fuel advancements in AptameX technology and enhance the reach of the Teman Sehat app, potentially leading to new market entries and partnerships within the global healthcare ecosystem. Achiko's commitment to innovation in disease diagnostics and digital health management suggests a future focused on scalable solutions for public health challenges.
See full Achiko company page
